|
124 Companies |
|
161 Products |
|
161 Products |
|
116 Mechanisms of Action |
|
11 Trials |
|
2428 News |
|
| «12...1718192021222324252627...4950» |
- Trial primary completion date: Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions (clinicaltrials.gov) - May 27, 2014
P=N/A, N=500, Recruiting, Sponsor: Valme University Hospital
Trial primary completion date: Sep 2013 --> Sep 2014
- Trial completion date: Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions (clinicaltrials.gov) - May 27, 2014
P=N/A, N=500, Recruiting, Sponsor: Valme University Hospital
Trial primary completion date: Sep 2013 --> Sep 2014 Trial completion date: Sep 2013 --> Dec 2014
- | emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
New P4 trial: PREP-5: PRe-Exposure Prophylaxis Acceptability & Readiness Assessments for Toronto gaY, Bisexual and Other Men Who Have Sex With Men-5 (clinicaltrials.gov) - May 27, 2014
P4, N=50, Not yet recruiting, Sponsor: St. Michael's Hospital, Toronto
- ||||| darunavir/ritonavir / Generic mfg.
New P4 trial: DUAL: Study to Evaluate Darunavir/Ritonavir + Lamivudine Versus Continuing With Darunavir/Ritonavir + Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV Infected Subject (clinicaltrials.gov) - May 26, 2014
P4, N=256, Not yet recruiting, Sponsor: Fundacion SEIMC-GESIDA
- emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Clinical: PrEP-India: Demonstrating Safety and Effective Delivery of Daily Oral Pre-exposure Prophylaxis (PrEP) for Sex Workers in India (clinicaltrials.gov) - May 26, 2014
P0, N=2000, Not yet recruiting, Sponsor: University of Manitoba
- ||||| daclatasvir/sofosbuvir / Generic mfg.
Enrollment closed, Combination therapy, IO biomarker: A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection. (clinicaltrials.gov) - May 26, 2014
P3, N=200, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Sep 2013 --> Dec 2014 Recruiting --> Active, not recruiting
- | Tivicay (dolutegravir) / ViiV Healthcare
Trial completion: Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult Subjects (clinicaltrials.gov) - May 21, 2014
P1, N=30, Completed, Sponsor: ViiV Healthcare
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Clinical: COMO: Cognition Study With HIV+ Patients (CTNPT 015) (clinicaltrials.gov) - May 20, 2014
P0, N=25, Recruiting, Sponsor: Marie-Josée Brouillette
- Intelence (etravirine) / J&J
Trial primary completion date: FAST: The First Failure Study (clinicaltrials.gov) - May 19, 2014
P4, N=3, Terminated, Sponsor: Imperial College London
Active, not recruiting --> Completed Trial primary completion date: Dec 2012 --> May 2013
- Trial primary completion date: The CogNaive Study: Assessing Changes in Neurocognitive Function in Treatment Na (clinicaltrials.gov) - May 19, 2014
P4, N=21, Completed, Sponsor: Imperial College London
Trial primary completion date: Dec 2012 --> May 2013 Trial primary completion date: Dec 2011 --> Dec 2012
- Intelence (etravirine) / J&J
Trial termination: FAST: The First Failure Study (clinicaltrials.gov) - May 19, 2014
P4, N=3, Terminated, Sponsor: Imperial College London
Trial primary completion date: Dec 2011 --> Dec 2012 Recruiting --> Terminated
- erlotinib / Generic mfg.
Trial initiation date, Surgery, Metastases: Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection (clinicaltrials.gov) - May 19, 2014
P1, N=36, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Terminated Initiation date: May 2014 --> Jul 2014
- Intelence (etravirine) / J&J
Trial completion date: FAST: The First Failure Study (clinicaltrials.gov) - May 19, 2014
P4, N=3, Terminated, Sponsor: Imperial College London
Initiation date: May 2014 --> Jul 2014 Trial completion date: Dec 2012 --> May 2013
- Intelence (etravirine) / J&J
Enrollment change: FAST: The First Failure Study (clinicaltrials.gov) - May 19, 2014
P4, N=3, Terminated, Sponsor: Imperial College London
Trial completion date: Dec 2012 --> May 2013 N=44 --> 3
- | Enrollment change: The CogNaive Study: Assessing Changes in Neurocognitive Function in Treatment Na (clinicaltrials.gov) - May 19, 2014
P4, N=21, Completed, Sponsor: Imperial College London
N=44 --> 3 N=40 --> 21
- | Trial completion: The CogNaive Study: Assessing Changes in Neurocognitive Function in Treatment Na (clinicaltrials.gov) - May 19, 2014
P4, N=21, Completed, Sponsor: Imperial College London
N=40 --> 21 Recruiting --> Completed
- artemether/lumefantrine / Generic mfg.
Trial primary completion date: Pharmacology of Antimalarial Therapy With or Without Antiretroviral Therapy (clinicaltrials.gov) - May 15, 2014
P4, N=19, Terminated, Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Recruiting --> Completed Trial primary completion date: Dec 2014 --> Mar 2014
- || lopinavir/ritonavir / Generic mfg.
Trial primary completion date: Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet (clinicaltrials.gov) - May 15, 2014
P=N/A, N=3000, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Dec 2014 --> Mar 2014 Trial primary completion date: Nov 2017 --> Dec 2017
- Trial primary completion date: IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults (clinicaltrials.gov) - May 15, 2014
P=N/A, N=168, Completed, Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Trial primary completion date: Nov 2017 --> Dec 2017 Trial primary completion date: Dec 2015 --> Mar 2014
- artemether/lumefantrine / Generic mfg.
Trial termination: Pharmacology of Antimalarial Therapy With or Without Antiretroviral Therapy (clinicaltrials.gov) - May 15, 2014
P4, N=19, Terminated, Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Trial primary completion date: Dec 2015 --> Mar 2014 Recruiting --> Terminated; Slow accrual and funding limitations.
- artemether/lumefantrine / Generic mfg.
Trial completion date: Pharmacology of Antimalarial Therapy With or Without Antiretroviral Therapy (clinicaltrials.gov) - May 15, 2014
P4, N=19, Terminated, Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Recruiting --> Terminated; Slow accrual and funding limitations. Trial completion date: Feb 2015 --> Mar 2014
- | lopinavir/ritonavir / Generic mfg.
Trial completion date: Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet (clinicaltrials.gov) - May 15, 2014
P=N/A, N=3000, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial completion date: Feb 2015 --> Mar 2014 Trial completion date: Nov 2017 --> Dec 2017
- Trial completion date: IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults (clinicaltrials.gov) - May 15, 2014
P=N/A, N=168, Completed, Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Trial completion date: Nov 2017 --> Dec 2017 Trial completion date: May 2016 --> Mar 2014
- artemether/lumefantrine / Generic mfg.
Enrollment change: Pharmacology of Antimalarial Therapy With or Without Antiretroviral Therapy (clinicaltrials.gov) - May 15, 2014
P4, N=19, Terminated, Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Trial completion date: May 2016 --> Mar 2014 N=48 --> 19
- Trial completion: IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults (clinicaltrials.gov) - May 15, 2014
P=N/A, N=168, Completed, Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group
N=48 --> 19 Active, not recruiting --> Completed
- | Vocabria (cabotegravir oral) / ViiV Healthcare
New P1 trial: Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Levonorgestrel and Ethinyl Estradiol When Co-administered With GSK1265744 in Healthy Adult Female Subjects (clinicaltrials.gov) - May 14, 2014
P1, N=24, Not yet recruiting, Sponsor: ViiV Healthcare
- Trial withdrawal: A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 Administered as an Oral Suspension to Healthy Adult Subjects (clinicaltrials.gov) - May 14, 2014
P1, N=0, Withdrawn, Sponsor: ViiV Healthcare
Active, not recruiting --> Completed Terminated --> Withdrawn
- Trial primary completion date: OPG-2: Effect of HIV Infection and Highly Active Antiretroviral Treatment (HAART) on Bone Homeostasis (clinicaltrials.gov) - May 14, 2014
P=N/A, N=120, Recruiting, Sponsor: Emory University
Terminated --> Withdrawn Trial primary completion date: Jan 2014 --> Feb 2015
- Trial completion date: OPG-2: Effect of HIV Infection and Highly Active Antiretroviral Treatment (HAART) on Bone Homeostasis (clinicaltrials.gov) - May 13, 2014
P=N/A, N=120, Recruiting, Sponsor: Emory University
Trial primary completion date: Jan 2014 --> Feb 2015 Trial completion date: Jan 2014 --> Feb 2015
- Ogsiveo (nirogacestat) / SpringWorks Therap
New P2 trial: Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma (clinicaltrials.gov) - May 12, 2014
P2, N=20, Not yet recruiting, Sponsor: AIDS Malignancy Clinical Trials Consortium
- ||| Aptivus (tipranavir) / Boehringer Ingelheim
Trial completion, Combination therapy: Pharmacokinetics and Safety Study of Tipranavir in Combination With Low Dose Ritonavir in Human Immunodeficiency Virus (HIV)-Infected Children (clinicaltrials.gov) - May 10, 2014
P1, N=115, Completed, Sponsor: Boehringer Ingelheim
Trial completion date: Jan 2014 --> Feb 2015 Active, not recruiting --> Completed
- Trial primary completion date: Positively Smoke Free on the Web (PSFW) for Smokers Living With HIV (clinicaltrials.gov) - May 8, 2014
P1/2, N=138, Completed, Sponsor: Georgetown University
Active, not recruiting --> Completed Trial primary completion date: May 2013 --> Jul 2013
- | New P1/2 trial: Asha II: Asha Improving Health and Nutrition of Indian Women With AIDS and Their Children (clinicaltrials.gov) - May 8, 2014
P1/2, N=600, Recruiting, Sponsor: University of California, Los Angeles
- Trial completion: Positively Smoke Free on the Web (PSFW) for Smokers Living With HIV (clinicaltrials.gov) - May 8, 2014
P1/2, N=138, Completed, Sponsor: Georgetown University
Trial primary completion date: May 2013 --> Jul 2013 Enrolling by invitation --> Completed
- Trial primary completion date: Testing a Secondary Prevention Intervention for HIV-Positive Black Young Men Who Have Sex With Men (clinicaltrials.gov) - May 7, 2014
P=N/A, N=80, Active, not recruiting, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Enrolling by invitation --> Completed Trial primary completion date: Apr 2014 --> May 2014
- Trial completion date: Testing a Secondary Prevention Intervention for HIV-Positive Black Young Men Who Have Sex With Men (clinicaltrials.gov) - May 7, 2014
P=N/A, N=80, Active, not recruiting, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Trial primary completion date: Apr 2014 --> May 2014 Trial completion date: Apr 2014 --> May 2014
- erlotinib / Generic mfg.
New P1 trial, Surgery, Metastases: Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection (clinicaltrials.gov) - May 7, 2014
P1, N=36, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- New P1 trial: Relationship of Tenofovir With HIV-1 Suppression in ex Vivo Tissue in Adolescents (clinicaltrials.gov) - May 7, 2014
P1, N=24, Not yet recruiting, Sponsor: University of California, Los Angeles
- |||| daclatasvir/sofosbuvir / Generic mfg.
Trial primary completion date, Combination therapy, IO biomarker: A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection. (clinicaltrials.gov) - May 6, 2014
P3, N=200, Recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Apr 2014 --> May 2014 Trial primary completion date: Oct 2014 --> Nov 2014
- |||| Trial primary completion date: PRINCE2: Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients (clinicaltrials.gov) - May 6, 2014
P3, N=95, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Oct 2014 --> Nov 2014 Trial primary completion date: Feb 2015 --> Sep 2014
- Hiltonol (poly-ICLC) / Oncovir
Trial primary completion date: DCVax Plus Poly ICLC in Healthy Volunteers (clinicaltrials.gov) - May 6, 2014
P1, N=43, Completed, Sponsor: Rockefeller University
Trial primary completion date: Feb 2015 --> Sep 2014 Trial primary completion date: May 2013 --> Nov 2012
- ||| censavudine (TPN-101) / Transposon Therap, Yale University
Trial initiation date: Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive (clinicaltrials.gov) - May 6, 2014
P2b, N=300, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: May 2013 --> Nov 2012 Initiation date: Jan 2012 --> Feb 2011
- ||||| Trial initiation date: PRINCE2: Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients (clinicaltrials.gov) - May 6, 2014
P3, N=95, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Initiation date: Jan 2012 --> Feb 2011 Initiation date: Jul 2011 --> May 2011
- ||| daclatasvir/sofosbuvir / Generic mfg.
Trial completion date, Combination therapy, IO biomarker: A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection. (clinicaltrials.gov) - May 6, 2014
P3, N=200, Recruiting, Sponsor: Bristol-Myers Squibb
Initiation date: Jul 2011 --> May 2011 Trial completion date: Jan 2015 --> Feb 2015
- || censavudine (TPN-101) / Transposon Therap, Yale University
Trial completion date: Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive (clinicaltrials.gov) - May 6, 2014
P2b, N=300, Recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Jan 2015 --> Feb 2015 Trial completion date: Aug 2017 --> Aug 2014
- Hiltonol (poly-ICLC) / Oncovir
Trial completion date: DCVax Plus Poly ICLC in Healthy Volunteers (clinicaltrials.gov) - May 6, 2014
P1, N=43, Completed, Sponsor: Rockefeller University
Trial completion date: Aug 2017 --> Aug 2014 Trial completion date: May 2013 --> Nov 2012
- |||| Rukobia (fostemsavir) / ViiV Healthcare
Enrollment open: HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections (clinicaltrials.gov) - May 6, 2014
P2b, N=250, Recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: May 2013 --> Nov 2012 Active, not recruiting --> Recruiting
- |||| censavudine (TPN-101) / Transposon Therap, Yale University
Enrollment open: Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive (clinicaltrials.gov) - May 6, 2014
P2b, N=300, Recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Recruiting Active, not recruiting --> Recruiting
- ||||| Enrollment closed: PRINCE2: Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients (clinicaltrials.gov) - May 6, 2014
P3, N=95, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- Hiltonol (poly-ICLC) / Oncovir
Trial completion: DCVax Plus Poly ICLC in Healthy Volunteers (clinicaltrials.gov) - May 6, 2014
P1, N=43, Completed, Sponsor: Rockefeller University
Recruiting --> Active, not recruiting Active, not recruiting --> Completed